Fig. 1.

Robust hematopoietic chimerism after CD117-ADC conditioning and transient immunosuppression in fully MHC-mismatched BM allotransplantation. a Experimental protocol. b–f Abbreviations: ADC, antibody-drug-conjugate; CD117, anti-CD117 mAb; ISO, isotype control mAb. b Donor peripheral blood chimerism showing CD117-ADC efficacy. Data are from day 100 post BMT and are summarized as the mean ± SEM from one (^a) or two (^b) independent experiments. CD117-Ab, 2 animals each for unconjugated CD117 mAbs 2B8 and ACK2. The underlying FACS gating strategy is given in Supplementary Figure 4. c Engraftment time course. Each line represents an individual mouse from a single experiment. The underlying FACS gating strategy is given in Supplementary Figure 4. d Immune organ chimerism. The underlying FACS gating strategy is given in Supplementary Figure 5. e Chimerism of mature leukocytes in spleen and BM. The underlying FACS gating strategy is given in Supplementary Figure 6. f BM progenitor chimerism. LT-HSC, long-term-HSCs (Lin^-Sca1⁺c-Kit⁺CD34^loFlt3^lo); ST-HSCs, short-term-HSCs (Lin^-Sca1⁺c-Kit⁺CD34^hiFlt3^lo); MPP, multipotent progenitors (Lin^-Sca1⁺c-Kit⁺CD34^hiFlt3^hi). The underlying FACS gating strategy is given in Supplementary Figure 7. b, d–f Data are the mean ± SEM donor chimerism at termination > 500 days after BMT. Statistics calculated using unpaired parametric t-tests with Welch’s correction (two-tailed); all data points significant as indicated (*P < 0.05; **P <0.01; ***P < 0.001; ****P < 0.0001). c–f Results are from one experiment representative of two independent experiments with 4–9 animals in each group